Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Capital Expenditures: 2021-2025

Historic Capital Expenditures for ARS Pharmaceuticals (SPRY) over the last 5 years, with Sep 2025 value amounting to -$5.5 million.

  • ARS Pharmaceuticals' Capital Expenditures fell 4043.57% to -$5.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $641,000, marking a year-over-year increase of 277.06%. This contributed to the annual value of $563,000 for FY2024, which is 221.71% up from last year.
  • As of Q3 2025, ARS Pharmaceuticals' Capital Expenditures stood at -$5.5 million, which was down 195.70% from $5.8 million recorded in Q2 2025.
  • ARS Pharmaceuticals' Capital Expenditures' 5-year high stood at $5.8 million during Q2 2025, with a 5-year trough of -$5.5 million in Q3 2025.
  • Its 3-year average for Capital Expenditures is $97,909, with a median of $83,000 in 2024.
  • Data for ARS Pharmaceuticals' Capital Expenditures shows a peak YoY increase of 15,081.58% (in 2025) and a maximum YoY decrease of 4,043.57% (in 2025) over the last 5 years.
  • Quarterly analysis of 5 years shows ARS Pharmaceuticals' Capital Expenditures stood at -$767,000 in 2021, then spiked by 116.43% to $126,000 in 2022, then plummeted by 172.22% to -$91,000 in 2023, then surged by 431.87% to $302,000 in 2024, then plummeted by 4,043.57% to -$5.5 million in 2025.
  • Its Capital Expenditures stands at -$5.5 million for Q3 2025, versus $5.8 million for Q2 2025 and $91,000 for Q1 2025.